[LS-33] Luncheon Seminar 33　The Importance of Evidence-Based Anti-CD20 Therapies

[LS-33-2] Ofatumumab Real World Data in 535 Japanese MS Patients

Takahiko Saida (Kansai MS Center/Irino Medical Clinic, Kyoto Miniren Chuo Hospital, Japan)